cyrilzakka/clinical-trials huggingface dataset:
Colposcopy in Detection of Oral Epithelial Dysplasia

The aim of this work is to detect the diagnostic accuracy of the intra-oral application of colposcope in diagnosing oral dysplastic lesions in comparison to biopsy taking and histopathological examination.

A- Roles and Responsibilities:

1. The Principle Supervisor: Dr. Mohsen Kazem (M.K.), Professor of Oral \&Maxillofacial Pathology, Cairo University, will examine the taken biopsy histopathologically and determine the definitive diagnosis.
2. The Assistant Supervisor: Dr. Heba Dahmoush (H.D.), Professor of Oral \& Maxillofacial Pathology, Cairo University, will examine the taken biopsy histopathologically and determine the definitive diagnosis.
3. The Principle Investigator: Sarah Ahmed Mohamed Mahmoud Badawy (S.B.), Assistant Lecturer of Oral \&Maxillofacial Pathology, Cairo University, will read and put a colposcopic score for each participant individually.
4. Eman Desouky (E.D.) Sample size calculation; Statistician, Faculty of Oral and Dental Medicine, Cairo University, Egypt.
5. Evidence Based Committee, Faculty of Dentistry, Cairo University: Help in reporting study protocol following STARD guidelines.
6. Ethics Committee, Faculty of Dentistry, Cairo University: Protocol reviewer of the diagnostic accuracy study in order to protect the right, safety, dignity and well-being of the participants.

B- Index test: The principle investigator (S.B.) will perform the index test using Digital Electronic Colposcope (Kernel, KN-2200, China). Before taking up the patients for Colposcopic evaluation and giving them a score, the normal Colposcopic findings will be standardized based on the Colposcopic criteria. Colposcopic criteria includes aceto uptake, surface pattern and clarity of demarcation of the mucosal lesions, vascular pattern, lesion size as well as Iodine staining.

C- Reference test:The reference standard; to reach a definitive diagnosis in oral dysplastic lesions, will be a representative biopsy and histopathological examination. M.K. and H.D. will examine the taken biopsy histopathologically, determine the definitive diagnosis and write the diagnosis in the Assessor chart.

Inclusion criteria:

* Patients seeking for diagnosis of clinically suspected oral dysplastic Leukoplakia or Erythroplakia
* Patients seeking for diagnosis of clinically suspected oral Carcinoma.

Exclusion criteria:

* Patients with secondary infection.
* Patients having other systemic diseases.
* Patients undergoing treatment for the lesions.

Eligibility Criteria:
Inclusion Criteria:

* Patients seeking for diagnosis of clinically suspected oral dysplastic Leukoplakia or Erythroplakia
* Patients seeking for diagnosis of clinically suspected oral Carcinoma.

Exclusion Criteria:

* Patients with secondary infection.
* Patients having other systemic diseases.
* Patients undergoing treatment for the lesions.
Electrocardiogram (ECG) Recordings in Paediatric Population

The primary goal of this protocol is to collect ECG signals from paediatric patients using 4 surface electrodes placed in the configurations proposed for the Cameron Health, Inc. subcutaneous implantable defibrillator (S-ICD) system. These signals will then be used to test the S-ICD system for future use in paediatric patients.

The surface ECGs collected from pediatric patients in normal sinus rhythm and a variety of ventricular and atrial arrhythmias will be used as test signals for the development of the S-ICD system. These signals will be collected from patients undergoing electrophysiology (EP) study, transvenous defibrillator implantation or ablation procedures

Eligibility Criteria:
Inclusion Criteria:

* Patients \< 18 years of age
* Patient scheduled for an EP study, implantation of an ICD or for an ablation procedure

Exclusion Criteria:

* Patients whose parents/guardians do not sign an informed consent
Effects of Concentric Exercise With and Without Mulligan Wrist Mobilization After Distal Radius Fracture.

The distal end of the radius is defined as the area three centimeters proximal to the radio carpal joint, where the radius interfaces with the lunate and scaphoid bone of the wrist. A fracture of the distal radius is usually caused by falling on the outstretched arm. The majority of distal radial fractures are closed injuries in which the overlying skin remains intact. Pain, swelling, bruising, deformity and deformity in the forearm or wrist are common. In women, the incidence of distal radial fracture increases with age from 40 years. The objective of this study will be to determine the Effects of Concentric exercises with and without mulligan wrist mobilization on pain, grip strength, Range of motion and function after distal radius fracture.

This study will be a randomized controlled trial and will be conducted in District Head Quarter hospital sheikhupura. The study will be completed in time duration of six months after the approval of synopsis and convenience sampling technique will be used. 18 subjects will be divided in two groups. Group A will follow concentric exercises at wrist including flexion, extension, abduction, adduction, pronation, supination and wrist mobilizations with movements while group B will follow only wrist concentric exercises treatment. MWM based on Mulligan's Recommendation that the patient should not experience any pain. The Location and direction of the glide could be modified so that the MWM was pain free, as advocated in the Mulligan concept. This study will be of 4 weeks, 3 sessions per week. Data will be collected by all participants before 1st session after 6th session and at the end of 12th session by using NPRS, Hand Dynamometer, Goniometer and Patient Rated Wrist Evaluation score. Data will be analyzed by SPSS-25.


Eligibility Criteria:
Inclusion Criteria:

* Age: 35-70 years
* Subjects with at least 6 weeks of distal radius fracture
* Orthopedic surgeon advise

Exclusion Criteria:

* Neurological problem affecting upper limb
* Parkinson disease
* Subjects having polyarthritis, bleeding disorders, tumors, local infection, peripheral vascular disease
* Any contraindication to physiotherapy
RECURRENCE OF ROTATOR CUFF LESION AFTER SURGICAL REPAIR WITH SINGLE-ROW vs DOUBLE-ROW SUTURE BRIDGE TECNIQUE: A COMPARATIVE STUDY

The rotator cuff is a muscle-tendon complex consisting of the tendons of the supraspinatus, subspinatus, subscapularis, and small round muscles capable of allowing movement of the shoulder joint in the various planes of space and stabilizing the glenohumeral joint.

Rotator cuff tendon injuries are very common. In most cases, these injuries are mostly degenerative based, as they are related to the aging process of the individual. However, it is increasingly common to diagnose such injuries in young individuals as well.

The reported incidence of rotator cuff injuries ranges from 5% to 40%, and of course the prevalence increases with age until it reaches 51% in patients older than 80 years.

The diagnosis of rotator cuff injury is made based on clinical examination and instrumental investigations such as Nuclear Magnetic Resonance Imaging (MRI).

Rotator cuff repair involves the use of anchors with included suture threads that allow the tendons to be returned to the level of the anatomical insertion, called the footprint.

Suture technique varies depending on the extent of injury and tendon and bone quality.

Single-row (single row) or double-row suture bridge (double-row suture bridge) anchoring techniques are currently a hotly debated topic in the literature.


Eligibility Criteria:
Inclusion Criteria:

* Patients aged ≥45 years with a diagnosis of full-thickness rotator cuff injury \<2cm
* Arthroscopic rotator cuff repair surgery with single row or double row suture bridge
* Follow-up \> 24 months
* Completeness of clinical-radiographic documentation
* Patients at first rotator cuff repair surgery on affected side

Exclusion Criteria:

* Patients with associated injuries to the affected upper limb
* Patients with neuromuscular disorders, or established psychomotor disorders
* Patients with associated injuries of the subscapularis muscle tendon
* Patients with a history of previous surgery of the affected shoulder
* Patients with massive rotator cuff injury \> 2cm
* Patients with severe pathologies of other organs or apparatuses that limit competitive or recreational sports activities
* Pregnant women
* Patients who cannot undergo high-field MRI (pcs with cochlear implants, cardiac, vascular or osteoarticular magnetic, pcs with previous gunshot wounds)
Determine the Bioequivalence of Two Formulations of Tamsulosin HCl Capsules in Fed Male.

Two tamsulosin HClformulations will be tested in fed state


Eligibility Criteria:
Inclusion criteria:

Health male volunteers 18 years and older

Exclusion criteria:

History of hypersensitivity or allergy to IMP or its excipients or any related medication
99mTc-CNDG SPECT/CT in Brain Tumors

The goal of this clinical trial is to evaluate the value of 99mTc-CNDG for diagnosis of brain tumors by comparing it with 18F-FDG-PET. The main questions it aims to answer are:

1. What is the diagnostic consistency between 99mTc-CNDG and 18F-FDG?
2. What is the correlation between the SUVmax value of 99mTc-CNDG and tumor type?

Participants will:

Receive18F-FDG-PET and 99mTc-CNDG examination within 2 weeks before surgery. Obtain pathological diagnosis by surgery or biopsy as the gold standard.


Eligibility Criteria:
Inclusion Criteria:

* Patients with clinical diagnosis of brain tumor;
* Be at least 18 years old;
* The final pathological results could be obtained by surgery or biopsy;
* Informed consent and the ability to be followed up;
* Those who did not meet the exclusion criteria.

Exclusion Criteria:

* Insulin-dependent diabetes mellitus or fasting blood glucose \>7 mmol/L before 99mTc-CNDG injection;
* Severe liver or kidney disease (serum creatinine level \>3.0mg/dL or any liver enzyme level ≥ 5 times the upper limit of normal);
* Severe hypersensitivity or hypersensitivity to radiocontrast agents;
* Claustrophobia (inability to undergo SPECT/CT or PET/CT scans);
* Patients receiving radiotherapy and chemotherapy;
* Being pregnant or breastfeeding.
Involvement of the Physician in Primary Prevention and Pre-hospital Management of Stroke

Stroke is a growing disease. It is the first pathology responsible for acquired handicap, the second of dementia and the second cause of death in the world. In France, they are the leading cause of death in women and the third cause in men. Sequelae and disabilities also represent a significant financial cost for health insurance.

The early management of the treatment improves the patient's vital and functional prognosis. The ability of the patient to identify the signs of stroke requiring urgent consultation and proper orientation are therefore crucial for further management.

The most common signs that patients must recognize are muscle weakness or sudden paralysis of an arm, leg or half of the body, asymmetry of the face, tingling, numbness of a hemi-body, speech or understanding, loss of vision of an eye or hemifield, disorder of the coordination of a hemi-body. The variety of clinical pictures complicates primary prevention.

In this context, a 2010-2014 National Stroke Action Plan was undertaken with the aim, among other things, of developing information to prevent stroke and to limit its sequelae. In this plan, the attending physician must improve prevention in high-risk patients and be a link between the city and the hospital for follow-up.

Several questions arise:

* Are patients who are regularly followed by a general practitioner better educated on the signs of stroke / TIA and thus more able to give an appropriate warning?
* What is the profile of patients who have not been affected by the different modes of primary prevention?
* What are the effective means of information and those desired


Eligibility Criteria:
Inclusion Criteria:

* Patient whose age is ≥ 18 years
* Patient hospitalized in the neurology / neurovascular department within the GHPSJ following a stroke (first episode or recurrence)
* Francophone patient

Exclusion Criteria:

* Patient with previously labeled cognitive impairment
* Patient under tutorship or curatorship
* Patient deprived of liberty
* Patient unable to answer the questionnaire
* Patient opposing participation in the study
MSC - OneBiome UX Pilot Study

Evaluating the user (pregnant women and parents of young children) experience of the OneBiome consumers value journey service offered to the 1000 days and young children consumers market

The OneBiome service aims to empower consumers with microbiome science in a friendly/consumer centric manner. The investigators wants to show that microbiome data can be used as an estimate of consumer's health and can be translated into actionable insights. The investigators aim to pilot a consumers' insight study to measure the perception/sentiments of this service in the Singapore market by recruiting study subjects from local public/private hospitals.

Eligibility Criteria:
Inclusion Criteria:

1. Pregnant women who are in the third trimester, or children from birth to 5 years of age
2. Pregnant women or parents of children should have access to the internet and a smartphone or tablet to access the OneBiome mobile friendly website.
3. Pregnant women or parents of children should be able to comprehend the content in the OneBiome mobile friendly website and complete the questionnaires in English.
4. Pregnant women and parents of children should stay in Singapore and remain contactable should they decide to do two microbiome assessments within 8 weeks

Exclusion Criteria:

1. Children born prematurely
2. Incapability of the pregnant women or parents of children to access OneBiome mobile friendly website and complete the questionnaires in English.
3. Any other family member is enrolled in the study
4. Incapability of the pregnant women or parents of children to comply with study protocol or Investigator's uncertainty about the willingness or ability of the pregnant women or parents of children to comply with the protocol requirements
Electromyography Triggered Functional Electrical Stimulation on Stroke Patients

my study aims to apply treatment program for postural instability in stroke patients.

my study include two groups: first group receive physical therapy exercise program followed by balance exercise program.

the second group receive the same physical therapy exercise program followed by balance exercise program conducted with electromyography triggered functional electrical stimulation

Eligibility Criteria:
Inclusion Criteria:

* stroke patients
* normal body mass index
* mild spasticity

Exclusion Criteria:

* musculoskeletal deformities
* cognitive abnormalities
* cardiovascular diseases
Multimodal Functional Imaging Combined With Metabolomics in Predicting the Efficacy of nCRT for Locally Advanced ESCC

Esophageal cancer (EC) is the seventh most frequently diagnosed cancers and the sixth leading causes of cancer death worldwide . It is one of the most common malignancy in China, with the third highest morbidity and mortality rate. More than 90% of patients with EC in China have esophageal squamous cell carcinoma (ESCC). Neoadjuvant chemoradiotherapy (nCRT) followed by surgery is currently widely used strategy for locally advanced surgical EC.

At present, conventional imaging methods have certain defects (focus only on the volume change) in the evaluation of the efficacy of nCRT. Whereas functional imaging can more comprehensively reflect the biological and microstructural characterization of tumors. The changes of these aspects of tumors can be observed earlier than volumetric changes of tumors.

The normal metabolism of the body is the basis for ensuring life activities. Due to the increased energy demand and proliferation of tumor tissue in patients with cancer, the metabolism of patients is different from that of normal person. Thus, the metabolic alterations seen in cancer cells have emerged as one of the hallmarks of cancer. Previous metabolomic studies have demonstrated various metabolic alterations in patients with ESCC. Many metabolites have been found to be promising diagnostic, staging or prognostic biomarkers for ESCC. However, there are few studies on metabolic markers on the chemoradiation sensitivity of esophageal cancer.

Therefore, the aim of the present study is to evaluate the value of functional imaging parameters and metabolic markers in assessing and predicting pathological response in patients who underwent nCRT for ESCC.


Eligibility Criteria:
Inclusion Criteria:

* Pathologically confirmed esophageal squamous cell carcinoma；
* AJCC 7th edition staging T3-T4a or N+；
* No radiotherapy or chemotherapy in the past；
* 18-75 years old；
* Hematology, biochemical and organ function indicators meet the following requirements: 1) White blood cells ≥ 3.0 x109/ L; 2)neutrophil cells ≥ 1.5 x109/ L; 3) Platelet count ≥85 x109/L; 4) Hemoglobin ≥90 g/L; 5) Total bilirubin ≤1.5 times normal value; 6) ALT≤ 1.5 x normal value; AST ≤1.5 times the normal value; 7) Serum creatinine ≤1.5 times the normal value, and creatinine clearance rate (Ccr) ≥60ml/min (Cockcroft-Gault);
* ECOG score 0-1 points;
* Able to eat a semi-liquid diet；
* sign an informed consent.

Exclusion Criteria:

* Have received radiotherapy or systemic chemotherapy;
* During pregnancy or lactation;
* Uncontrollable serious medical diseases;
* Unable to sign informed consent;
* With distant metastasis;
* Suffering from the second type of malignant tumor (except skin squamous cell carcinoma and carcinoma in situ of other organs) within the past 5 years；
* Those who cannot receive MRI examination;
* Chemotherapy drugs or contrast agents Allergic.
ICMNC-HF. IntraCoronary Bone Marrow MonoNuclear Cells in Heart Failure (HF) Patients

This is a prospective, randomised double blind, controlled, parallel-group phase I and II study. Its aim is to assess that a single intracoronary infusion of autologous bone marrow-mononuclear cells is safe and effective in hear failure patients with reduced left ventricular ejection fraction(\<=30%) when compared to a control group of patients undergoing best medical care.


Eligibility Criteria:
Inclusion Criteria:

1. Men and women of any ethnic origin 18 ≤ aged≤ 65 years
2. EF≤40 (by Echocardiography) and regional wall motion abnormality
3. Not responding to standard therapies
4. the New York Heart Association (NYHA) class ≥ III
5. Myocardial infarction due to coronary artery atherosclerotic disease
6. An area of regional dysfunction, i.e., hypokinetic, akinetic, or dyskinetic (echocardiography or MRI)
7. Normal liver and renal function
8. No or controlled diabetes
9. Able to give voluntary written consent and understand the study information provided to him

Exclusion Criteria:

1. Participation in another clinical trial within 30 days prior randomisation
2. Previously received stem/progenitor cell therapy
3. Pregnant women
4. Mental condition rendering the patient unable to understand the nature, scope and possible consequences of the study or to follow the protocol
5. Cardiogenic shock requiring mechanical support
6. Congenital / valvular heart disease
7. Implantable cardioverter defibrillator (ICD) transplant
8. Platelet count \<100.000/µl, or hemoglobin \<8.5 g/dl
9. Impaired renal function, i.e. creatinine \>2.5 mg/dl
10. Fever or diarrhea within 4 weeks prior screening
11. History of bleeding disorder within 3 months prior screening
12. Uncontrolled hypertension (systolic \>180 mmHg and diastolic \>120 mmHg) or Sustained ventricular arrhythmia
13. Life expectancy of less than two years from any non-cardiac cause or uncontrolled neoplastic disease
EPO906 Therapy in Patients With Advanced Ovarian, Primary Fallopian, or Primary Peritoneal Cancer

This study will examine whether the new investigational drug EPO906, given by intravenous infusion (IV directly into the vein), is effective in shrinking tumors and preventing the growth of cells that cause ovarian, fallopian, or peritoneal cancers. Recruitment in the United States is complete but the study is still enrolling in other countries.


Eligibility Criteria:
Inclusion Criteria:

The following patients may be eligible for the study:

* Histologically or cytologically documented evidence of ovarian, primary Fallopian or primary peritoneal cancer with at least one measurable lesion (if previous radiation treatment, the target lesion must have demonstrated progression since the radiation)
* Must have a life expectancy of greater than three (3) months
* Prior failure to respond following front-line treatment with a taxane and platinum (or a combination therapy) may be eligible.

Exclusion Criteria:

The following patients are not eligible for the study:

* Patients with radiation therapy or chemotherapy within the last four weeks
* Patients who have had any chemotherapy not containing a taxane and platinum for their disease
* Patients with borderline ovarian and macropapillary tumors
* Patients with unresolved bowel obstruction
* Patients with symptomatic CNS metastases or leptomeningeal involvement
* Patients with any peripheral neuropathy or unresolved diarrhea greater than Grade 1
* Patients with severe cardiac insufficiency
* Patients taking Coumadin or other warfarin-containing agents with the exception of low dose Coumadin (1 mg or less) for the maintenance of in-dwelling lines or ports
* History of another malignancy within 5 years prior to study entry except curatively treated non-melanoma skin cancer or cervical cancer in situ
* Patients with active or suspected acute or chronic uncontrolled infection including abcesses or fistulae
* HIV+ patients
* Pregnant or lactating females.
Preoxygenation in the Intensive Care Unit Using a Nose-mouth Mask Versus High-flow Nasal Cannula Oxygen.

Preoxygenation is routinely performed before endotracheal intubation. In the intensive care unit, preoxygenation is often accomplished using a nose-mouth mask. It seems probable that high flow nasal cannula oxygen, which is used in the treatment of patients with hypoxemic respiratory failure, is equally effective in preventing the development of hypoxemia during intubation. In this prospective randomized study preoxygenation using high flow nasal cannula oxygen is compared with preoxygenation via nose-mouth mask in patients with hypoxemic respiratory failure.


Eligibility Criteria:
Inclusion Criteria:

* patients treated in an intensive care unit
* indication for intubation
* presence of hypoxemic (SaO2/fraction of inspired oxygen(FiO2): 300 or less) respiratory failure
* informed consent

Exclusion Criteria:

* blocked nasopharynx
* contraindications for nose-mouth mask or high flow nasal cannula oxygen
* expected difficult airway